Unlike large biopharma firms, most small biotech companies usually have their fortunes riding on only a single drug. If a small firm’s product fails a Phase II trial, do you think the smart move is to keep working on its product candidate instead of entirely scrapping the project?
Poll Question:
If a firm’s only candidate fails a Phase II trial, should it push on with development?
Yes
25
No
32
Undecided
17
